Reich K, et al. - By performing this review, researchers focused on the long-term effectiveness as well as the safety profile of secukinumab (a fully human monoclonal antibody that selectively binds and neutralises interleukin-17A) in the management of plaque psoriasis and its various manifestations from its Phase 3 clinical trial programme. Secukinumab has displayed sustainable efficacy and safety up to 5 years in skin plaque psoriasis (PsO), psoriatic arthritis, and ankylosing spondylitis, as revealed in the long-term extension of pivotal trials, and it was found safe and effective for up to 2.5 years in moderate-to-severe nail and palmoplantar PsO as reported in dedicated randomised controlled trials. The influence of secukinumab treatment in all these indications has corresponding impacts on improvement in quality-of-life and daily activities. Findings revealed the effectiveness as well as the safety of secukinumab as a therapeutic option for patients experiencing psoriatic disease in its various clinical variants.